News

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency, reproducibility, and ...
At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.
Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...
Bisoprolol is reaffirmed as a key cardioselective Beta-1-blocker across the cardiovascular disease (CVD) continuum, with a ...
The intervention tested was the Conducted AF-Response Algorithm (CAFR), a device-based algorithm designed to optimize biventricular stimulation in patients with atrial fibrillation. The study compared ...
AI’s diagnostic makeover is unfolding across every layer of medicine. Discover how it's helping doctors today!
The study began in February 2004, with its primary completion and estimated completion dates not specified. The last update was submitted on June 30, 2025. These dates are crucial as they indicate the ...
Most heart problems are asymptomatic at early stages as they generally develop slowly over many years. Damage to the arteries, which can lead to heart attacks and strokes, results from many small ...
Looking for easy snacks for heart disease that fit a busy lifestyle? Discover 7 nutritious snacks, such as hummus with whole-grain crackers and apples with peanut butter, that support the management ...
There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.
The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid ...
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...